Your session is about to expire
← Back to Search
Photodynamic Therapy for Head and Neck Cancer
Study Summary
This trial is testing a new cancer treatment that uses light-sensitive drugs and laser light to kill cancer cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My tumor cannot be treated with I-PDT due to its location or size.I can take care of myself and am up and about more than half of my waking hours.My cancer has spread to a major blood vessel.I am currently pregnant or breastfeeding.You have a condition called porphyria or are allergic to substances called porphyrins or similar compounds.My tumor can be reached for light-based treatment as decided by my doctor.My tumor cannot be measured using CT or MRI scans.I am eligible for treatments like chemotherapy, targeted therapy, immunotherapy, or other approved methods for my condition.I do not have brain metastases.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.My kidney function is not severely impaired.My doctor thinks I shouldn't receive porfimer sodium.I have not had radiotherapy in the last 30 days in the area that needs treatment.My head or neck cancer has not improved with standard treatments and cannot be cured with usual methods.
- Group 1: Arm A (standard of care chemotherapy at doctor's discretion)
- Group 2: Arm B(porfimer sodium, I-PDT, SoC chemotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned the use of Pembrolizumab?
"Pembrolizumab has been granted a safety rating of 2 due to limited data confirming its efficacy, which is expected when the drug is in Phase 2 clinical trials."
Is this research endeavor still recruiting participants?
"According to clinicaltrials.gov, this experiment is actively recruiting patients as of now. It was introduced on July 10th 2019 and most recently updated September 27th 2022."
How many participants can this clinical trial accommodate?
"Affirmative. According to clinicaltrials.gov, the trial was initially listed on July 10th 2019 and has recently been updated on September 27th 2022. Eighty-two individuals are needed for this investigation at one study site."
What maladies does Pembrolizumab typically target?
"Pembrolizumab is regularly deployed to treat unresectable melanoma, and can be used as a safeguard against microsatellite instability high, squamous cell carcinoma, or the possibly of recurrence."
Share this study with friends
Copy Link
Messenger